People’s Vaccine

The supply of safe and effective vaccines for all is being artificially rationed because of the protection of exclusive rights and monopolies of pharmaceutical corporations, the People’s Vaccine Alliance said today.

In response to Johnson & Johnson's and Novovax release of Phase 3 Trial results of their respective COVID-19 vaccines, Niko Lusiani, Senior Advisor with Oxfam America, said: 

“Today marks yet another hopeful achievement in the fight against the coronavirus. Thanks to tireless scientific efforts, and funding from taxpayers like you and me, these two new vaccines could help turn the corner in the battle against the COVID-19 pandemic. The speed that the virus is mutating is only reinforcing the need for mass-produced vaccines available to everyone, everywhere, as soon as possible." 

The news that the Sanofi/GSK vaccine will not be ready until the end of 2021 is a bitter blow for poorer nations. Sanofi-GSK was set to provide nearly one third of COVAX doses – the global vaccine purchasing facility upon which many of the poorest countries depend. 

Commenting at the close of the EU council meeting where leaders agreed on a new EU 2030 climate target and discussed the EU’s response to the Covid-19 pandemic, Evelien van Roemburg, head of Oxfam’s EU advocacy office said: "The new, more ambitious, EU 2030 target still falls short of what is needed and what is fair. The EU must take urgent practical steps to deliver above and beyond this target."

Nearly 70 poor countries will only be able to vaccinate one in ten people against COVID-19 next year unless urgent action is taken by governments and the pharmaceutical industry to make sure enough doses are produced.

“Moderna’s discovery could be a real game-changer in the fight against COVID-19. However, on its own, Moderna can only produce enough vaccine for less than seven percent of the global population by the end of 2021, almost all of whom will be in rich countries," said Anna Marriott, Oxfam’s Health Policy Manager, in response to the announcement today from the National Institutes of Health that early data shows Moderna’s COVID-19 vaccine is nearly 95 percent effective.

Responding to the World Bank's proposal of a $12 billion initiative to help poor countries purchase COVID-19 vaccines, Anna Marriott, Health Policy Advisor at Oxfam, said: "The World Bank is right to be concerned about whether poorer countries will be able to afford COVID-19 vaccines and treatments and they should use their influence accordingly."

Survivors of COVID-19 from 37 countries are among almost 1,000 people who have signed an open letter to pharmaceutical industry leaders calling for a ‘people's vaccine’ and treatments that are available to all – free from patents. The letter comes on the eve of a high-level side event about the pandemic at the UN General Assembly in New York.

Wealthy nations representing just 13 percent of the world’s population have already cornered more than half (51 percent) of the promised doses of leading COVID-19 vaccine candidates, Oxfam warned today as the health and finance ministers of G20 countries meet to discuss the global pandemic.